19X.F Axsome Therapeutics Inc
- Market cap
- EUR 7.01B
- P/E
- -
- P/B
- 70.48x
- ROE
- -162.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 19X.F undervalued?
Graham numberThe Graham number of Axsome Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Axsome Therapeutics Inc fundamental analysis
No fundamental analysis for Axsome Therapeutics Inc yet.
Axsome Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and n…
Full company profileAxsome Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Axsome Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.82M | 50.0M | 271M | 386M | 638M | 892M |
| Gross Profit | - | - | - | - | 0.00 | 0.00 | 44.8M | 245M | 352M | 591M | 831M |
| Operating Income | -27.1M | -27.0M | -32.6M | -67.1M | -99.1M | -125M | -177M | -183M | -252M | -169M | -170M |
| EBITDA | - | -27.6M | -29.8M | -67.1M | -100M | -124M | -174M | -225M | -273M | -168M | -154M |
| Net Income | -27.2M | -28.9M | -31.0M | -68.3M | -103M | -130M | -187M | -239M | -287M | -183M | -172M |
| EPS | - | -1.14 | -1.03 | -1.85 | -2.75 | -3.45 | -4.30 | -5.05 | -5.90 | -3.60 | -3.26 |
| Balance Sheet | |||||||||||
| Total Assets | 38.2M | 35.6M | 15.4M | 221M | 186M | 87.8M | 331M | 588M | 568M | 690M | 827M |
| Total Liabilities | 16.6M | 18.8M | 14.4M | 41.8M | 72.3M | 72.2M | 222M | 397M | 511M | 602M | 721M |
| Shareholders' Equity | 21.6M | 16.7M | 938K | 179M | -279M | 15.6M | 110M | 191M | 57.0M | 88.3M | 105M |
| Cash & Short-term Investments | 36.6M | 34.0M | 14.0M | 220M | 184M | 86.5M | 201M | 386M | 315M | 323M | 314M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -21.3M | -26.5M | -30.1M | -46.4M | -78.5M | -108M | -117M | -145M | -128M | -93.4M | -84.2M |
| Capital Expenditure | 105K | 9.90K | 32.7K | 16.1K | 45.9K | 308K | 702K | 582K | 270K | 480K | 1.02M |
| Free Cash Flow | - | -26.5M | -30.1M | -46.4M | -78.5M | -109M | -117M | -146M | -129M | -93.9M | -85.2M |
| Ratios | |||||||||||
| ROE | -126.1% | -173.1% | -3,301.5% | -38.2% | - | -834.3% | -170.8% | -125.3% | -503.8% | -207.5% | -162.8% |
| ROA | -71.2% | -81.4% | -201.3% | -31.0% | -55.3% | -148.5% | -56.5% | -40.7% | -50.5% | -26.6% | -20.8% |
| Net Profit Margin | - | - | - | - | - | -1,478.5% | -374.0% | -88.4% | -74.5% | -28.7% | -19.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Axsome Therapeutics Inc dividends
Axsome Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Axsome Therapeutics Inc
- Insiders 15.02%
- Institutions 75.26%
- Public & others 9.72%
- Shares outstanding 52.6M
- Free float 44.7M
Axsome Therapeutics Inc company profile
- Company name
- Axsome Therapeutics Inc
- Ticker
- 19X.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,390
- Fiscal year end
- December
- Address
- One World Trade Center, New York, NY, United States, 10007
- Phone
- 212 332 3241
- Website
- axsome.com
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Axsome Therapeutics Inc management
6- Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & President · born 1968
- Mr. Nick Pizzie CPA, M.B.A.Chief Financial Officer · born 1975
- Mr. Mark L. Jacobson M.A.Chief Operating Officer · born 1983
- Mr. Hunter Murdock Esq.General Counsel & Secretary · born 1980
- Mr. Ari Maizel M.B.A.Chief Commercial Officer · born 1979
- Darren OplandDirector of Corporate Communications